We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Seviprotimut-L for Malignant Melanoma after Surgery

< Back

Seviprotimut-L for Malignant Melanoma after Surgery


Cancer and Palliative Care

June 2018

Melanoma is a type of skin cancer that can appear anywhere on the body and usually begins with a mole. The back, legs and face are commonly affected areas of the body. Melanoma is the fifth most common cancer in the UK with a third of people diagnosed under the age of 55 years. Malignant melanoma indicates that the melanoma cells have spread deeper into the skin, lymph vessels or lymph glands close to the melanoma. Treatment of melanoma by surgery is often successful at first, but may begin to fail as the cancer spreads and enters end-stage disease. Treatments following tumour removal in malignant melanoma are not widely used in UK practice.
Seviprotimut-L is a type of cancer vaccine that is being developed for the treatment of adult patients with malignant melanoma who have had surgical resection. It is designed to stimulate the body’s immune system to fight cancer cells, to stop the cancer coming back. Seviprotimut-L is injected under the skin in different parts of the body. The unique way it acts may offer a new treatment option for malignant melanoma patients after surgery.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts